Honolulu Heart Program (HHP) - Catalog

  • Name

    Honolulu Heart Program (HHP)

  • Accession Number

    HLB00070023a

  • Acronym

    HHP

  • Related studies
  • BSI Study IDs

    HHS

  • Is public use dataset

    False

  • Keywords
  • Has Study Datasets

    True

  • Has Specimens

    True

  • Specimen ID Type
    Coded
  • Study Website
  • The Framingham Heart Study Group requires that the requestor must obtain full or expedited IRB/Ethics Committee review and approval to obtain these data. Waivers or a determination that the research is exempt from ethical regulations do not suffice.

    False

  • Clinical Trial URLs
    NCT00005123
  • Study type
    Epidemiology Study
  • Collection Type
    Open BioLINCC Study
  • Cohort type
    Adult
  • Interventions
  • Study Open Date (Data)

    2009-10-01

  • Study Open Date (Specimens)

    2010-09-24

  • Date materials available

    2008-10-13

  • Last updated

    2005-06-23

  • Study period

    1965-1998

  • Study Contacts
  • NHLBI Division

    DCVS

  • Classification
    Heart
  • HIV study classification
    non-HIV
  • COVID study classification
    non-COVID
  • Pre-Website # of Specimens Shipped

    1876

  • # of Returned Specimens

    0

  • Primary Publication URLs
    N/A
  • Commercial use data restrictions
    No
  • Data restrictions based on area of research
    No
  • Commercial use specimen restrictions
    No
  • Non-genetic use specimen restrictions based on area of use
    No
  • Genetic use of specimens allowed?
    Yes
  • Genetic use area of research restrictions
    No
  • Specific Consent Restrictions
  • Conditions
    Aortic Aneurysm, Abdominal
    Asthma
    Bronchitis
    Cardiovascular Diseases
    Cerebrovascular Accident
    Chronic Obstructive Pulmonary Disease
    Coronary Disease
    Dementia
    Emphysema
    Heart Diseases
    Heart Failure
    Heart Failure, Congestive
    Hypertension
    Lung Diseases, Obstructive
    Myocardial Infarction
  • Objectives

    The initial objectives of the Honolulu Heart Program were to: 1) estimate morbidity and mortality from coronary heart disease and stroke among Japanese men in Honolulu; 2) compare morbidity and mortality from coronary heart disease and stroke among Japanese men in Japan, Honolulu, and San Francisco; 3) investigate relationships among risk factors, coronary heart disease, and stroke in Japanese men in Honolulu; 4) compare distributions of risk factors among men in Japan, Honolulu, and San Francisco, and relate similarities and differences in risk factors to the occurrence of disease in these areas and in other populations, including Framingham and Puerto Rico; 5) conduct an autopsy study, and to relate pathological findings to morbidity and mortality data; and 6) investigate relationships between risk factors and pathological evidence of atherosclerosis and its complications.

  • Background

    The Honolulu Heart Program was initiated in 1965 by the NHLBI as a prospective study of environmental and biological causes of cardiovascular disease among Japanese Americans living in Hawaii. This population was known to have low incidence of coronary heart disease and higher incidence of stroke. The study provided opportunities to investigate relationships among disease frequencies, pathologic findings, and disease predictors in the cohort and to compare the findings in this population with those in other populations, especially cohorts of Japanese men resident in Japan or the U.S.

  • Participants

    American men of Japanese ancestry born in 1900-1919 and living on the island of Oahu in 1965; age at entry 28-62 years; sample size: 8,006.

  • Design

    The study began in 1965 with the first examination of a cohort of 8,006 Japanese-American men residing on the island of Oahu, Hawaii who were born during the period 1900-1919. The first examination was completed in 1968 and was followed by the initiation of a second examination that same year. Three subsequent sub-examinations (Lipoprotein Exams I, II and III) were conducted between 1970 and 1982 to collect lipid measurements on a subset of those who participated in Exam 2. The fourth examination of surviving members of the original cohort was conducted during 1991-93 and collected data on 3,741 men. Morbidity and mortality follow-up continues through grant and contract-supported efforts, and the current HHP dataset includes events through 1998.

  • Conclusions
  • Disease classification
  • Publications
  • Mat types
    DNA
    Plasma
    Serum
  • Network

The study population available in BioLINCC study data may be lower than total study enrollment due to Informed Consent restrictions and other factors.

  • Subjects

    8008


    Last Modified: July 28, 2014, 3:44 p.m.
  • Age

     

    N

    %

    Unknown

    2

    0.02

    45 -< 50

    1859

    23.21

    50 -< 55

    2775

    34.65

    55 -< 60

    1593

    19.89

    60 -< 65

    1336

    16.68

    65 -< 70

    443

    5.53

    Last Modified: March 7, 2016, 4:33 p.m.
  • Sex

    Male


    Last Modified: July 28, 2014, 3:48 p.m.
  • Race

    Japanese-American


    Last Modified: July 28, 2014, 3:48 p.m.

Please note that biospecimen availability is subject to review by the NHLBI, BioLINCC, and the NHLBI Biorepository. Certain biospecimens may not be made available for your request. PDF Section 3.0 of the BioLINCC Handbook describes the components of the review process.

  • Material Types
  • General Freeze/Thaw Status
  • Visits (Vials)

    03/08/2021

      Serum Plasma DNA Total
    Examination 2 13,621 75 0 13,696
    Examination 3 5,211 0 0 5,211
    Examination 4 14,949 23,503 10,853 49,305
    Kittner Study 2,969 0 0 2,969
    Lipoproteins Examination 1 1,856 1,859 0 3,715
    Lipoproteins Examination 2 6,951 0 0 6,951
    Lipoproteins Examination 3 28 6,012 0 6,040
    Unknown 1,071 580 0 1,651

     

    Last Modified: March 8, 2021, 4:29 p.m.
  • Visits (Subjects)

    03/08/2021

      Serum
    Total number of subjects Average volume (ml) per subject
    Examination 2 2,812 3.71
    Examination 3 5,207 1.84
    Examination 4 3,500 3.88
    Kittner Study 1,434 3.71
    Lipoproteins Examination 1 1,398 5.71
    Lipoproteins Examination 2 2,361 9.01
    Lipoproteins Examination 3 24 1.60
    Unknown 488 10.16
     
      Plasma
    Total number of subjects Average volume (ml) per subject
    Examination 2 32 4.18
    Examination 4 3,614 5.54
    Lipoproteins Examination 1 1,059 3.86
    Lipoproteins Examination 3 1,740 3.37
    Unknown 575 0.87
     
      DNA
    Total number of subjects Average mass (µg) per subject Average vials per subject
    Examination 4 2,322 14.52 4.67

    Last Modified: March 8, 2021, 4:29 p.m.